We can’t show the full text here under this license. Use the link below to read it at the source.
Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans
Modeling how psilocybin and its active form move through the bodies of mice, rats, and humans
AI simplified
Abstract
A physiologically based pharmacokinetic model for psilocybin and its active metabolite, psilocin, has been developed for mice, rats, and humans.
- Psilocybin is a psychoactive compound that may have potential in treating major depressive disorder.
- The model explores how psilocin distributes in the body, particularly to the brain.
- Psilocybin is believed to fully convert to psilocin before entering systemic circulation.
- The model accurately characterizes concentration-time profiles for different dosing scenarios and administration routes.
- The human model could inform therapeutic strategies and support the design of clinical trials for psilocybin.
AI simplified